Báo cáo y học: "Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. | Cost Effectiveness and Resource Allocation BioMed Central Open Access Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States Nicolas M Furiak1 Haya Ascher-Svanum 2 Robert W Klein1 Lee J Smolen1 Anthony H Lawson2 Robert R Conley3 and Steven D Culler4 Address 1Medical Decision Modeling Inc. Indianapolis IN USA 2Eli Lilly and Company Indianapolis IN USA 3Lilly USA LLC Indianapolis IN USA and 4Emory University Atlanta GA USA Email Nicolas M Furiak - nf@ Haya Ascher-Svanum - haya@ RobertW Klein - rwk@ Lee J Smolen - leesmolen@ Anthony H Lawson - lawsonan@ Robert R Conley - rconley@ Steven D Culler - sculler@ Corresponding author Published 7 April 2009 Received 27 June 2008 Cost Effectiveness and Resource Allocation 2009 7 4 doi 1478-7547-7-4 Accepted 7 April 2009 This article is available from http content 7 1 4 2009 Furiak et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Schizophrenia is often a persistent and costly illness that requires continued treatment with antipsychotics. Differences among antipsychotics on efficacy safety tolerability adherence and cost have cost-effectiveness implications for treating schizophrenia. This study compares the cost-effectiveness of oral olanzapine oral risperidone at generic cost primary comparator quetiapine ziprasidone and aripiprazole in the treatment of patients with schizophrenia from the perspective of third-party payers in the . health care system. Methods A I-year microsimulation economic decision model with quarterly cycles was developed to simulate the dynamic .

Không thể tạo bản xem trước, hãy bấm tải xuống
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
8    87    1    29-06-2024
144    321    53    29-06-2024
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.